Key clinical point: Chemotherapy with PET-guided radiation therapy was inferior to combined modality therapy in patients with early-stage Hodgkin lymphoma.
Major finding: The 5-year progression-free survival in PET-negative patients was 93.4% with combined modality therapy, compared with 86.1% with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) alone.
Study details: A randomized phase 3 trial in 1,150 patients with early-stage favorable-risk Hodgkin lymphoma.
Disclosures: The study was supported by grants from Deutsche Krebshilfe and the Swiss State Secretariat for Education, Research, and Innovation. Dr. Fuchs reported honoraria from Amgen, Affimed, Celgene, and Takeda. Multiple coauthors reported industry funding.
Fuchs M et al. J Clin Oncol. 2019 Sep 10. doi: 10.1200/JCO.19.00964.